Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: stimuli-responsive carriers, co-delivery and suppressing resistance

References

• Cao W, He L, Cao W, et al. Recent progress of graphene oxide as a potential vaccine carrier and adjuvant. Acta Biomater. 2020;112:14–28.
   PubMed Web of Science ®Google Scholar
• Delfi M, Sartorius R, Ashrafizadeh M, et al. Self-assembled peptide and protein nanostructures for anti-cancer therapy: targeted delivery, stimuli-responsive devices and immunotherapy. Nano Today. 2021;38:101119.
   PubMed Web of Science ®Google Scholar
• Makvandi P, Baghbantaraghdari Z, Zhou W, et al. Gum polysaccharide/nanometal hybrid biocomposites in cancer diagnosis and therapy. Biotechnol Adv. 2021;48:107711.
   PubMed Web of Science ®Google Scholar
• Sharma H, Mondal S. Functionalized graphene oxide for chemotherapeutic drug delivery and cancer treatment: a promising material in nanomedicine. Int J Mol Sci. 2020;21(17):6280.
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu Y, Shen Y. Plasmonic-enhanced graphene oxide-based aquatic robot for target cargo delivery. ACS Appl Mater Interfaces. 2021;13(1):1503–1510.
   PubMed Web of Science ®Google Scholar
• Wu S, LIU Y, Zhang H, et al. Nano-graphene oxide with antisense vicR RNA reduced exopolysaccharide synthesis and biofilm aggregation for Streptococcus mutans . Dent Mater J. 2020;39(2):278–286. DOI:https://doi.org/10.4012/dmj.2019-039.
   PubMed Web of Science ®Google Scholar
• Singh V, Sagar P, Kaul S, et al. Liver phosphoenolpyruvate carboxykinase-1 downregulation via siRNA-functionalized graphene oxide nanosheets restores glucose homeostasis in a type 2 diabetes mellitus in vivo model. Bioconjug Chem. 2020;32:259–278.
   PubMed Web of Science ®Google Scholar
• Ghorbanzadeh R, Assadian H, Chiniforush N, et al. Modulation of virulence in Enterococcus faecalis cells surviving antimicrobial photodynamic inactivation with reduced graphene oxide-curcumin: an ex vivo biofilm model. Photodiagnosis Photodyn Ther. 2020;29:101643.
   PubMed Web of Science ®Google Scholar
• Deng X, Liang H, Yang W, et al. Polarization and function of tumor-associated macrophages mediate graphene oxide-induced photothermal cancer therapy. J Photochem Photobiol B. 2020;208:111913.
   PubMed Web of Science ®Google Scholar
• Burnett M, Abuetabh Y, Wronski A, et al. Graphene oxide nanoparticles induce apoptosis in wild-type and CRISPR/Cas9-IGF/IGFBP3 knocked-out osteosarcoma cells. J Cancer. 2020;11(17):5007–5023. DOI:https://doi.org/10.7150/jca.46464.
   PubMed Web of Science ®Google Scholar
• Barrera CC, Groot H, Vargas WL, et al. Efficacy and molecular effects of a reduced graphene Oxide/Fe(3)O(4) nanocomposite in photothermal therapy against cancer. Int J Nanomedicine. 2020;15:6421–6432.
   PubMed Web of Science ®Google Scholar
• Pei X, Zhu Z, Gan Z, et al. PEGylated nano-graphene oxide as a nanocarrier for delivering mixed anticancer drugs to improve anticancer activity. Sci Rep. 2020;10(1):2717. DOI:https://doi.org/10.1038/s41598-020-59624-w.
   PubMed Web of Science ®Google Scholar
• Mostafavi E, Medina-Cruz D, Kalantari K, et al. Electroconductive nanobiomaterials for tissue engineering and regenerative medicine. Bioelectricity. 2020;2(2):120–149. DOI:https://doi.org/10.1089/bioe.2020.0021.
   PubMedGoogle Scholar
• Alam AU, Deen MJ. Bisphenol a electrochemical sensor using graphene oxide and β-cyclodextrin-functionalized multi-walled carbon nanotubes. Anal Chem. 2020;92(7):5532–5539.
   PubMed Web of Science ®Google Scholar
• Matharu RK, Tabish TA, Trakoolwilaiwan T, et al. Microstructure and antibacterial efficacy of graphene oxide nanocomposite fibres. J Colloid Interface Sci. 2020;571:239–252.
   PubMed Web of Science ®Google Scholar
• Yu H, Marchetti L, Parlanti P, et al. High-efficient synthesis of graphene oxide based on improved hummers method. Sci Rep. 2016;6(1):1–7. DOI:https://doi.org/10.1038/s41598-016-0001-8.
   PubMed Web of Science ®Google Scholar
• Tufano I, Vecchione R, Netti PA. Methods to scale down graphene oxide size and size implication in anti-cancer applications. Front Bioeng Biotechnol. 2020;8:1381.
   Web of Science ®Google Scholar
• Bianco A, Cheng, H. M, Enoki, T, et al. All in the graphene family–a recommended nomenclature for two-dimensional carbon materials.2013;65:1–6.
   Google Scholar
• Mostafavi E, Soltantabar P, Webster TJ. Nanotechnology and picotechnology: a new arena for translational medicine. In: Yang L, Bhaduri S, Webster T. J, editors. Biomaterials in translational medicine. Elsevier; 2019. p. 191–212.
   Google Scholar
• Srinivasan M, Rajabi M, Mousa SA. Nanobiomaterials in cancer therapy. In Nanobiomaterials in cancer therapy. William Andrew Publishing; 2016. p. 57–89. DOI:https://doi.org/10.1016/B978-0-323-42863-7.00003-7.
   Google Scholar
• López-Diaz D, Merchán MD, Velázquez MM. The behavior of graphene oxide trapped at the air water interface. Adv Colloid Interface Sci. 2020;286:102312.
   PubMed Web of Science ®Google Scholar
• Marcano DC, Kosynkin DV, Berlin JM, et al. Improved synthesis of graphene oxide. ACS nano. 2010;4(8):4806–4814. DOI:https://doi.org/10.1021/nn1006368.
   PubMed Web of Science ®Google Scholar
• López-Díaz D, López Holgado M, García-Fierro JL, et al. Evolution of the Raman spectrum with the chemical composition of graphene oxide. J Phys Chem C. 2017;121(37):20489–20497. DOI:https://doi.org/10.1021/acs.jpcc.7b06236.
   Web of Science ®Google Scholar
• Dimiev A, Kosynkin DV, Alemany LB, et al. Pristine graphite oxide. J Am Chem Soc. 2012;134(5):2815–2822. DOI:https://doi.org/10.1021/ja211531y.
   PubMed Web of Science ®Google Scholar
• Dimiev AM, Tour JM. Mechanism of graphene oxide formation. ACS nano. 2014;8(3):3060–3068.
   PubMed Web of Science ®Google Scholar
• He H, Riedl T, Lerf A, et al. Solid-state NMR studies of the structure of graphite oxide. J Phys Chem. 1996;100(51):19954–19958. DOI:https://doi.org/10.1021/jp961563t.
   Web of Science ®Google Scholar
• Lerf A,He, H, Riedl, T, et al. 13C and 1H MAS NMR studies of graphite oxide and its chemically modified derivatives. Solid State Ion. 1997;101-103:857–862.
   Web of Science ®Google Scholar
• Lerf A, He H, Forster M, et al. Structure of graphite oxide revisited. J Phys Chem A. 1998;102(23):4477–4482. DOI:https://doi.org/10.1021/jp9731821.
   Web of Science ®Google Scholar
• Gao W, Alemany LB, Ci L, et al. New insights into the structure and reduction of graphite oxide. Nat Chem. 2009;1(5):403–408. DOI:https://doi.org/10.1038/nchem.281.
   PubMed Web of Science ®Google Scholar
• Ren X, Su C. Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma. Mol Med Rep. 2020;22(3):2183–2190.
   PubMed Web of Science ®Google Scholar
• Decker CW, Garcia J, Gatchalian K, et al. Mitofusin-2 mediates doxorubicin sensitivity and acute resistance in Jurkat leukemia cells. Biochem Biophys Rep. 2020;24:100824.
   PubMedGoogle Scholar
• Tanaka I,Chakraborty, A, Saulnier, O, et al. ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Res. 2020;48(5):2676–2693.
   PubMed Web of Science ®Google Scholar
• Nowroozi N, Faraji S, Nouralishahi A, et al. Biological and structural properties of graphene oxide/curcumin nanocomposite incorporated chitosan as a scaffold for wound healing application. Life Sci. 2021;264:118640.
   PubMed Web of Science ®Google Scholar
• Esmaeili E, Eslami-Arshaghi T, Hosseinzadeh S, et al. The biomedical potential of cellulose acetate/polyurethane nanofibrous mats containing reduced graphene oxide/silver nanocomposites and curcumin: antimicrobial performance and cutaneous wound healing. Int J Biol Macromol. 2020;152:418–427.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zhang Q, Lay Yap P, et al. Magnetic reduced graphene oxide as a nano-vehicle for loading and delivery of curcumin. Spectrochim Acta A Mol Biomol Spectrosc. 2021;252:119471.
   PubMed Web of Science ®Google Scholar
• Patil R, Patel H, Pillai SB, et al. Influence of surface oxygen clusters upon molecular stacking of paclitaxel over graphene oxide sheets. Mater Sci Eng C Mater Biol Appl. 2020;116:111232.
   PubMed Web of Science ®Google Scholar
• Wei L, Lu Z, Ji X, et al. Self-assembly of hollow graphene oxide microcapsules directed by cavitation for loading hydrophobic drugs. ACS Appl Mater Interfaces. 2021;13(2):2988–2996. DOI:https://doi.org/10.1021/acsami.0c16550.
   PubMed Web of Science ®Google Scholar
• Deb A, Andrews NG, Raghavan V. Honokiol-camptothecin loaded graphene oxide nanoparticle towards combinatorial anti-cancer drug delivery. IET Nanobiotechnol. 2020;14(9):796–802.
   PubMed Web of Science ®Google Scholar
• Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157–170.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Hashemi F, et al. Polychemotherapy with curcumin and doxorubicin via biological nanoplatforms: enhancing antitumor activity. Pharmaceutics. 2020;12(11):1084. DOI:https://doi.org/10.3390/pharmaceutics12111084.
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Zarrabi A, Hashemi F, et al. Nrf2 signaling pathway in chemoprotection and doxorubicin resistance: potential application in drug discovery. Antioxidants (Basel). 2021;10(3). DOI:https://doi.org/10.3390/antiox10030349.
   Google Scholar
• Poh HM, Chiou Y, Chong Q, et al. Inhibition of TFF3 enhances sensitivity-and overcomes acquired resistance-to doxorubicin in estrogen receptor-positive mammary carcinoma. Cancers (Basel). 2019;11(10):1528. DOI:https://doi.org/10.3390/cancers11101528.
   Web of Science ®Google Scholar
• Dai X, Ahn KS, Wang LZ, et al. Ascochlorin enhances the sensitivity of doxorubicin leading to the reversal of epithelial-to-mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther. 2016;15(12):2966–2976. DOI:https://doi.org/10.1158/1535-7163.MCT-16-0391.
   PubMed Web of Science ®Google Scholar
• Abbas MM, Kandil Y, Abbas MA. R-(-)-carvone attenuated doxorubicin induced cardiotoxicity in vivo and potentiated its anticancer toxicity in vitro. Balkan Med J. 2020;37(2):98–103.
   PubMed Web of Science ®Google Scholar
• Hilmer SN, Cogger VC, Muller M, et al. The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab Dispos. 2004;32(8):794–799. DOI:https://doi.org/10.1124/dmd.32.8.794.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Pavlidis P, Chua S, et al. An ancestral haplotype defines susceptibility to doxorubicin nephropathy in the laboratory mouse. J Am Soc Nephrol. 2006;17(7):1796–1800. DOI:https://doi.org/10.1681/ASN.2005121373.
   PubMed Web of Science ®Google Scholar
• Wang Y,Wang, Y.P, Tay, Y.C, et al. Progressive Adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 2000;58(4):1797–1804. DOI:https://doi.org/10.1046/j.1523-1755.2000.00342.x.
   PubMed Web of Science ®Google Scholar
• Rook M, Lely AT, Kramer AB, et al. Individual differences in renal ACE activity in healthy rats predict susceptibility to Adriamycin-induced renal damage. Nephrol Dialysis Transplantation. 2005;20(1):59–64. DOI:https://doi.org/10.1093/ndt/gfh579.
   PubMed Web of Science ®Google Scholar
• Soltantabar P, Calubaquib EL, Mostafavi E, et al. Enhancement of loading efficiency by coloading of doxorubicin and quercetin in thermoresponsive polymeric micelles. Biomacromolecules. 2020;21(4):1427–1436. DOI:https://doi.org/10.1021/acs.biomac.9b01742.
   PubMed Web of Science ®Google Scholar
• Gonçalves M, Mignani S, Rodrigues J, et al. A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market. J Control Release. 2020;317:347–374.
   PubMed Web of Science ®Google Scholar
• Rajendran P, Li F, Manu KA, et al. γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br J Pharmacol. 2011;163(2):283–298. DOI:https://doi.org/10.1111/j.1476-5381.2010.01187.x.
   PubMed Web of Science ®Google Scholar
• Rajendran P, Ong TH, Chen L, et al. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res. 2011;17(6):1425–1439. DOI:https://doi.org/10.1158/1078-0432.CCR-10-1123.
   PubMed Web of Science ®Google Scholar
• Rajendran P, Li F, Shanmugam MK, et al. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J Cell Physiol. 2012;227(5):2184–2195. DOI:https://doi.org/10.1002/jcp.22954.
   PubMed Web of Science ®Google Scholar
• Hortobágyi G. Anthrazykline in der Krebstherapie: ein Überblick. Drugs. 1997;54:1–7.
   PubMed Web of Science ®Google Scholar
• Yang F, Teves SS, Kemp CJ, et al. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta (BBA)- Rev Cancer. 2014;1845(1):84–89. DOI:https://doi.org/10.1016/j.bbcan.2013.12.002.
   PubMed Web of Science ®Google Scholar
• Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440. DOI:https://doi.org/10.1097/FPC.0b013e32833ffb56.
   PubMed Web of Science ®Google Scholar
• ?A3B2 tlsb -0.04w?Wang Y, Zhou P, Li P, et al. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1. Bioengineered. 2020;11(1):536–546. DOI:https://doi.org/10.1080/21655979.2020.1761512.
   PubMed Web of Science ®Google Scholar
• Ghandhariyoun N,Jaafari, M.R,Taghdisi, S.M, et al. Reducing Doxorubicin resistance in breast cancer by liposomal FOXM1 aptamer: in vitro and in vivo. Life Sci. 2020;262:118520.
   PubMed Web of Science ®Google Scholar
• Casagrande N, Borghese C, Favero A, et al. Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma. Cancer Lett. 2021;500:182–193.
   PubMed Web of Science ®Google Scholar
• ?A3B2 tlsb -0.04w?Karai E,Szebényi, K, Windt, T, et al. Celecoxib prevents doxorubicin-induced multidrug resistance in canine and mouse lymphoma cell lines. Cancers (Basel). 2020;12(5):1117. DOI:https://doi.org/10.3390/cancers12051117.
   Web of Science ®Google Scholar
• Amani N, Shokrzadeh M, Shaki F. Clarithromycin effectively enhances doxorubicin-induced cytotoxicity and apoptosis in MCF7 cells through dysregulation of autophagy. Adv Med Sci. 2020;65(2):235–243.
   PubMed Web of Science ®Google Scholar
• Rolle F, Bincoletto V, Gazzano E, et al. Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells. Int J Pharm. 2020;580:119191.
   PubMed Web of Science ®Google Scholar
• Li Y, Tan X, Liu X, et al. Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-Corona for dual suppression of drug resistance. Asian J Pharm Sci. 2020;15(5):646–660. DOI:https://doi.org/10.1016/j.ajps.2019.10.003.
   PubMed Web of Science ®Google Scholar
• ?A3B2 tlsb -0.04w?Al Saqr A, Aldawsari MF, Alrbyawi H, et al. Co-delivery of hispolon and doxorubicin liposomes improves efficacy against melanoma cells. AAPS PharmSciTech. 2020;21(8):304. DOI:https://doi.org/10.1208/s12249-020-01846-2.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Kotcherlakota R, Haque S, et al. Improved delivery of doxorubicin using rationally designed PEGylated platinum nanoparticles for the treatment of melanoma. Mater Sci Eng C. 2020;108:110375.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhou Y, Zhang CY, et al. Co-delivery of paclitaxel and doxorubicin by ph-responsive prodrug micelles for cancer therapy. Int J Nanomedicine. 2020;15:3319–3331.
   PubMed Web of Science ®Google Scholar
• ?A3B2 tlsb -0.04w?Liu M, Peng Y, Nie Y, et al. Co-delivery of doxorubicin and DNAzyme using ZnO@polydopamine core-shell nanocomposites for chemo/gene/photothermal therapy. Acta Biomater. 2020;110:242–253.
   PubMed Web of Science ®Google Scholar
• Kashyap D, Tuli HS, Yerer MB, et al. Natural product-based nanoformulations for cancer therapy: opportunities and challenges. Semin Cancer Biol. 2021;69:5–23.
   PubMed Web of Science ®Google Scholar
• Li Y, Hou H, Zhang P, et al. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy. Drug Deliv. 2020;27(1):1044–1053. DOI:https://doi.org/10.1080/10717544.2020.1785049.
   PubMed Web of Science ®Google Scholar
• Babos G, Rydz J, Kawalec M, et al. Poly(3-hydroxybutyrate)-based nanoparticles for sorafenib and doxorubicin anticancer drug delivery. Int J Mol Sci. 2020;21(19):7312. DOI:https://doi.org/10.3390/ijms21197312.
   Web of Science ®Google Scholar
• Zhang R, Zhang Y, Zhang Y, et al. Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than Doxil(Ⓡ). Asian J Pharm Sci. 2020;15(3):385–396. DOI:https://doi.org/10.1016/j.ajps.2019.04.007.
   PubMed Web of Science ®Google Scholar
• Chen Y, Du Q, Zou Y, et al. Co-delivery of doxorubicin and epacadostat via heparin coated pH-sensitive liposomes to suppress the lung metastasis of melanoma. Int J Pharm. 2020;584:119446.
   PubMed Web of Science ®Google Scholar
• Medatwal N, Ansari MN, Kumar S, et al. Hydrogel-mediated delivery of celastrol and doxorubicin induces a synergistic effect on tumor regression via upregulation of ceramides. Nanoscale. 2020;12(35):18463–18475. DOI:https://doi.org/10.1039/D0NR01066A.
   PubMed Web of Science ®Google Scholar
• Chen X,Niu, S, Bremner, D.H, et al. Co-delivery of doxorubicin and oleanolic acid by triple-sensitive nanocomposite based on chitosan for effective promoting tumor apoptosis. Carbohydr Polym. 2020;247:116672.
   PubMed Web of Science ®Google Scholar
• Yang K,Wan, J, Zhang, S, et al. The influence of surface chemistry and size of nanoscale graphene oxide on photothermal therapy of cancer using ultra-low laser power. Biomaterials. 2012;33(7):2206–2214.
   PubMed Web of Science ®Google Scholar
• Zhang W, Guo Z, Huang D, et al. Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide. Biomaterials. 2011;32(33):8555–8561. DOI:https://doi.org/10.1016/j.biomaterials.2011.07.071.
   PubMed Web of Science ®Google Scholar
• Ma X, Tao H, Yang K, et al. A functionalized graphene oxide-iron oxide nanocomposite for magnetically targeted drug delivery, photothermal therapy, and magnetic resonance imaging. Nano Res. 2012;5(3):199–212. DOI:https://doi.org/10.1007/s12274-012-0200-y.
   Web of Science ®Google Scholar
• Du P, Yan J, Long S, et al. Tumor microenvironment and NIR laser dual-responsive release of berberine 9- O -pyrazole alkyl derivative loaded in graphene oxide nanosheets for chemo-photothermal synergetic cancer therapy. J Mater Chem B. 2020;8(18):4046–4055. DOI:https://doi.org/10.1039/D0TB00489H.
   PubMed Web of Science ®Google Scholar
• Das P, Mudigunda SV, Darabdhara G, et al. Biocompatible functionalized AuPd bimetallic nanoparticles decorated on reduced graphene oxide sheets for photothermal therapy of targeted cancer cells. J Photochem Photobiol B. 2020;212:112028.
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun X, Huang T, et al. A sandwich nanostructure of gold nanoparticle coated reduced graphene oxide for photoacoustic imaging-guided photothermal therapy in the second NIR window. Front Bioeng Biotechnol. 2020;8:655.
   PubMed Web of Science ®Google Scholar
• Khan MS, Pandey S, Bhaisare ML, et al. Graphene oxide@gold nanorods for chemo-photothermal treatment and controlled release of doxorubicin in mice Tumor. Colloids Surf B Biointerfaces. 2017;160:543–552.
   PubMed Web of Science ®Google Scholar
• Wang L, Yu D, Dai R, et al. PEGylated doxorubicin cloaked nano-graphene oxide for dual-responsive photochemical therapy. Int J Pharm. 2019;557:66–73.
   PubMed Web of Science ®Google Scholar
• Lu YJ, Lin P-Y, Huang P-H, et al. magnetic graphene oxide for dual targeted delivery of doxorubicin and photothermal therapy. Nanomaterials (Basel). 2018;8(4):193. DOI:https://doi.org/10.3390/nano8040193.
   PubMedGoogle Scholar
• Zaharie-Butucel D, Potara M, Suarasan S, et al Efficient combined near-infrared-triggered therapy: phototherapy over chemotherapy in chitosan-reduced graphene oxide-IR820 dye-doxorubicin nanoplatforms. J Colloid Interface Sci. 2019;552:218–229.
   PubMed Web of Science ®Google Scholar
• Pramanik N, Ranganathan S, Rao S, et al. a composite of hyaluronic acid-modified graphene oxide and iron oxide nanoparticles for targeted drug delivery and magnetothermal therapy. ACS Omega. 2019;4(5):9284–9293. DOI:https://doi.org/10.1021/acsomega.9b00870.
   PubMed Web of Science ®Google Scholar
• Su T, Cheng F, Yan J, et al. Hierarchical nanocomposites of graphene oxide and PEGylated protoporphyrin as carriers to load doxorubicin hydrochloride for trimodal synergistic therapy. J Mater Chem B. 2018;6(28):4687–4696. DOI:https://doi.org/10.1039/C8TB00733K.
   PubMed Web of Science ®Google Scholar
• Kang S, Hong YL, Ku B-C, et al. Synthesis of biologically-active reduced graphene oxide by using fucoidan as a multifunctional agent for combination cancer therapy. Nanotechnology. 2018;29(47):475604. DOI:https://doi.org/10.1088/1361-6528/aadfa5.
   PubMed Web of Science ®Google Scholar
• Dong H,Jin, M, Liu, Z, et al. In vitro and in vivo brain-targeting chemo-photothermal therapy using graphene oxide conjugated with transferrin for Gliomas. Lasers Med Sci. 2016;31(6):1123–1131. DOI:https://doi.org/10.1007/s10103-016-1955-2.
   PubMed Web of Science ®Google Scholar
• Hu Y, Sun D, Ding J, et al. Decorated reduced graphene oxide for photo-chemotherapy. J Mater Chem B. 2016;4(5):929–937. DOI:https://doi.org/10.1039/C5TB02359A.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu K, Feng L, et al. Comparison of nanomedicine-based chemotherapy, photodynamic therapy and photothermal therapy using reduced graphene oxide for the model system. Biomater Sci. 2017;5(2):331–340. DOI:https://doi.org/10.1039/C6BM00526H.
   PubMed Web of Science ®Google Scholar
• Song J, Yang X, Jacobson O, et al. sequential drug release and enhanced photothermal and photoacoustic effect of hybrid reduced graphene oxide-loaded ultrasmall gold nanorod vesicles for cancer therapy. ACS Nano. 2015;9(9):9199–9209. DOI:https://doi.org/10.1021/acsnano.5b03804.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Omidi, M, Muralidharan, B, et al. Layer-by-layer assembly of graphene oxide on thermosensitive liposomes for photo-chemotherapy. Acta Biomater. 2018;65:376–392.
   PubMed Web of Science ®Google Scholar
• Mauro N, Scialabba C, Agnello S, et al. Folic acid-functionalized graphene oxide nanosheets via plasma etching as a platform to combine NIR anticancer phototherapy and targeted drug delivery. Mater Sci Eng C Mater Biol Appl. 2020;107:110201.
   PubMed Web of Science ®Google Scholar
• Kalluru P, Vankayala R, Chiang C-S, et al. Nano-graphene oxide-mediated In vivo fluorescence imaging and bimodal photodynamic and photothermal destruction of tumors. Biomaterials. 2016;95:1–10.
   PubMed Web of Science ®Google Scholar
• Yang Y,Shi, H, Wang, Y, et al. Graphene oxide/manganese ferrite nanohybrids for magnetic resonance imaging, photothermal therapy and drug delivery. J Biomater Appl. 2016;30(6):810–822. DOI:https://doi.org/10.1177/0885328215601926.
   PubMed Web of Science ®Google Scholar
• Han L, Hao Y-N, Wei X, et al. Hollow copper sulfide nanosphere-doxorubicin/graphene oxide core-shell nanocomposite for photothermo-chemotherapy. ACS Biomater Sci Eng. 2017;3(12):3230–3235. DOI:https://doi.org/10.1021/acsbiomaterials.7b00643.
   PubMed Web of Science ®Google Scholar
• Zhen SJ, Wang TT, Liu YX, et al. Reduced graphene oxide coated Cu 2−x Se nanoparticles for targeted chemo-photothermal therapy. J Photochem Photobiol B. 2018;180:9–16.
   PubMed Web of Science ®Google Scholar
• de Melo-diogo D, Costa EC, Alves CG, et al. POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells. Eur J Pharm Biopharm. 2018;131:162–169.
   PubMed Web of Science ®Google Scholar
• Huang X, Chen J, Wu W, et al. Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma. Acta Biomater. 2020;109:229–243.
   PubMed Web of Science ®Google Scholar
• Liao J, Zhang H, Wang X. Polydopamine-doped virus-like mesoporous silica coated reduced graphene oxide nanosheets for chemo-photothermal synergetic therapy. J Biomater Appl. 2020;35(1):28–38.
   PubMed Web of Science ®Google Scholar
• Yang H, Bremner DH, Tao L, et al. Carboxymethyl chitosan-mediated synthesis of hyaluronic acid-targeted graphene oxide for cancer drug delivery. Carbohydr Polym. 2016;135:72–78.
   PubMed Web of Science ®Google Scholar
• Tran TH, Nguyen HT, Pham TT, et al. Development of a graphene oxide nanocarrier for dual-drug chemo-phototherapy to overcome drug resistance in cancer. ACS Appl Mater Interfaces. 2015;7(51):28647–28655. DOI:https://doi.org/10.1021/acsami.5b10426.
   PubMed Web of Science ®Google Scholar
• Zheng T, Gao Y, Deng X, et al. Comparisons between graphene oxide and graphdiyne oxide in physicochemistry biology and cytotoxicity. ACS Appl Mater Interfaces. 2018;10(39):32946–32954. DOI:https://doi.org/10.1021/acsami.8b06804.
   PubMed Web of Science ®Google Scholar
• Wang H,Ahn, K.S, Alharbi, S.A, et al. Celastrol alleviates gamma irradiation-induced damage by modulating diverse inflammatory mediators. Int J Mol Sci. 2020;21(3):1084.
   PubMed Web of Science ®Google Scholar
• Subramaniam A, Loo SY, Rajendran P, et al. An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins. Apoptosis. 2013;18(10):1175–1187. DOI:https://doi.org/10.1007/s10495-013-0851-5.
   PubMed Web of Science ®Google Scholar
• Yoo W, Yoo D, Hong E, et al. Acid-activatable oxidative stress-inducing polysaccharide nanoparticles for anticancer therapy. J Control Release. 2018;269:235–244.
   PubMed Web of Science ®Google Scholar
• Ka H, Park H-J, Jung H-J, et al. Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells. Cancer Lett. 2003;196(2):143–152. DOI:https://doi.org/10.1016/S0304-3835(03)00238-6.
   PubMed Web of Science ®Google Scholar
• Dong K, Lei Q, Qi H, et al. Amplification of oxidative stress in mcf-7 cells by a novel ph-responsive amphiphilic micellar system enhances anticancer therapy. Mol Pharm. 2019;16(2):689–700. DOI:https://doi.org/10.1021/acs.molpharmaceut.8b00973.
   PubMed Web of Science ®Google Scholar
• Dong K,Zhao, Z.Z, Kang, J, et al. Cinnamaldehyde and doxorubicin co-loaded graphene oxide wrapped mesoporous silica nanoparticles for enhanced MCF-7 cell apoptosis. Int J Nanomedicine. 2020;15:10285–10304.
   PubMed Web of Science ®Google Scholar
• Bidram E,Sulistio, A, Cho, H.J, et al. Targeted graphene oxide networks: cytotoxicity and synergy with anticancer agents. ACS Appl Mater Interfaces. 2018;10(50):43523–43532. DOI:https://doi.org/10.1021/acsami.8b17531.
   PubMed Web of Science ®Google Scholar
• Quagliarini E,Di Santo, R, Pozzi, D, et al. Mechanistic Insights into the release of doxorubicin from graphene oxide in cancer cells. Nanomaterials (Basel). 2020;10(8):1482. DOI:https://doi.org/10.3390/nano10081482.
   Google Scholar
• Slekiene N, Snitka V. Impact of graphene oxide functionalized with doxorubicin on viability of mouse hepatoma MH-22A cells. Toxicol In Vitro. 2020;65:104821.
   PubMed Web of Science ®Google Scholar
• Zhu J, Xu M, Gao M, et al. Graphene oxide induced perturbation to plasma membrane and cytoskeletal meshwork sensitize cancer cells to chemotherapeutic agents. ACS Nano. 2017;11(3):2637–2651. DOI:https://doi.org/10.1021/acsnano.6b07311.
   PubMed Web of Science ®Google Scholar
• Gauthier F, Bertrand J-R, Vasseur -J-J, et al. Conjugation of doxorubicin to sirna through disulfide-based self-immolative linkers. Molecules. 2020;25(11):2714. DOI:https://doi.org/10.3390/molecules25112714.
   PubMed Web of Science ®Google Scholar
• Yang B, Hao A, Chen L. Mirror siRNAs loading for dual delivery of doxorubicin and autophagy regulation siRNA for multidrug reversing chemotherapy. Biomed Pharmacother. 2020;130:110490.
   PubMed Web of Science ®Google Scholar
• Vahidian F, Safarzadeh E, Mohammadi A, et al. siRNA-mediated silencing of CD44 delivered by Jet Pei enhanced Doxorubicin chemo sensitivity and altered miRNA expression in human breast cancer cell line (MDA-MB468). Mol Biol Rep. 2020;47(12):9541–9551. DOI:https://doi.org/10.1007/s11033-020-05952-z.
   PubMed Web of Science ®Google Scholar
• Ciocan-Cȃrtiţă CA, Jurj A, Raduly L, et al. New perspectives in triple-negative breast cancer therapy based on treatments with TGFβ1 siRNA and doxorubicin. Mol Cell Biochem. 2020;475(1–2):285–299. DOI:https://doi.org/10.1007/s11010-020-03881-w.
   PubMed Web of Science ®Google Scholar
• Norouzi P, Motasadizadeh H, Atyabi F, et al. Combination therapy of breast cancer by codelivery of doxorubicin and survivin sirna using polyethylenimine modified silk fibroin nanoparticles. ACS Biomater Sci Eng. 2021;7:1074–1087.
   PubMed Web of Science ®Google Scholar
• Joshi U, Filipczak N, Khan MM, et al. Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells. Int J Pharm. 2020;590:119915.
   PubMed Web of Science ®Google Scholar
• Zou Y, Sun X, Wang Y, et al. Single siRNA nanocapsules for effective sirna brain delivery and glioblastoma treatment. Adv Mater. 2020;32(24):e2000416. DOI:https://doi.org/10.1002/adma.202000416.
   PubMed Web of Science ®Google Scholar
• Wu B,Yuan, Y, Han, X, et al. Structure of LINC00511-siRNA-conjugated nanobubbles and improvement of cisplatin sensitivity on triple negative breast cancer. The FASEB Journal. 2020;34(7):9713–9726. DOI:https://doi.org/10.1096/fj.202000481R.
   PubMed Web of Science ®Google Scholar
• Shi M, Zhang J, Huang Z, et al. Stimuli-responsive release and efficient siRNA delivery in non-small cell lung cancer by a poly(l -histidine)-based multifunctional nanoplatform. J Mater Chem B. 2020;8(8):1616–1628. DOI:https://doi.org/10.1039/C9TB02764E.
   PubMed Web of Science ®Google Scholar
• Gencer A,Duraloglu, C, Ozbay, S, et al. Recent advances in treatment of lung cancer: nanoparticle-based drug and sirna delivery systems. Curr Drug Deliv. 2020;18(2):103–120.
   Web of Science ®Google Scholar
• Wan WJ, Qu C-X, Zhou Y-J, et al. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy. Int J Pharm. 2019;566:731–744.
   PubMed Web of Science ®Google Scholar
• Haghiralsadat F, Amoabediny G, Naderinezhad S, et al. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance. Int J Nanomedicine. 2018;13:3853–3866.
   PubMed Web of Science ®Google Scholar
• Sun Q, Wang X, Cui C, et al. Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo. Int J Nanomedicine. 2018;13:3713–3728.
   PubMed Web of Science ®Google Scholar
• Dioguardi M, Caloro GA, Laino L, et al. Circulating miR-21 as a potential biomarker for the diagnosis of oral cancer: a systematic review with meta-analysis. Cancers (Basel). 2020;12(4):936. DOI:https://doi.org/10.3390/cancers12040936.
   Web of Science ®Google Scholar
• Zhang HH, Huang Z-X, Zhong S-Q, et al. miR‑21 inhibits autophagy and promotes malignant development in the bladder cancer T24 cell line. Int J Oncol. 2020;56(4):986–998. DOI:https://doi.org/10.3892/ijo.2020.4984.
   PubMed Web of Science ®Google Scholar
• Najjary S, Mohammadzadeh R, Mokhtarzadeh A, et al. Role of miR-21 as an authentic oncogene in mediating drug resistance in breast cancer. Gene. 2020;738:144453.
   PubMed Web of Science ®Google Scholar
• Wang C, Kar S, Lai X, et al. Triple negative breast cancer in Asia: an insider’s view. Cancer Treat Rev. 2018;62:29–38.
   PubMed Web of Science ®Google Scholar
• Jia LY, Shanmugam MK, Sethi G, et al. Potential role of targeted therapies in the treatment of triple-negative breast cancer. Anticancer Drugs. 2016;27(3):147–155. DOI:https://doi.org/10.1097/CAD.0000000000000328.
   PubMed Web of Science ®Google Scholar
• Shanmugam MK, Ahn KS, Hsu A, et al. Thymoquinone inhibits bone metastasis of breast cancer cells through abrogation of the cxcr4 signaling axis. Front Pharmacol. 2018;9:1294.
   PubMed Web of Science ®Google Scholar
• Yang Z, Yang D, Zeng K, et al. simultaneous delivery of antimir-21 and doxorubicin by graphene oxide for reducing toxicity in cancer therapy. ACS Omega. 2020;5(24):14437–14443. DOI:https://doi.org/10.1021/acsomega.0c01010.
   PubMed Web of Science ®Google Scholar
• Phan QA, Truong LB, Medina-Cruz D, et al. CRISPR/Cas-powered nanobiosensors for diagnostics. Biosens Bioelectron. 2021;197:113732.
   PubMed Web of Science ®Google Scholar
• Mohammadinejad R, Dehshahri A, Sassan H, et al. Preparation of carbon dot as a potential CRISPR/Cas9 plasmid delivery system for lung cancer cells. Minerva Biotecnologica. 2020;32(3):106–113. DOI:https://doi.org/10.23736/S1120-4826.20.02618-X.
   Web of Science ®Google Scholar
• Wang P, Wang X, Tang Q, et al. Functionalized graphene oxide against U251 glioma cells and its molecular mechanism. Mater Sci Eng C Mater Biol Appl. 2020;116:111187.
   PubMed Web of Science ®Google Scholar
• Lee DY, Khatun Z, Lee J-H, et al. Blood compatible graphene/heparin conjugate through noncovalent chemistry. Biomacromolecules. 2011;12(2):336–341. DOI:https://doi.org/10.1021/bm101031a.
   PubMed Web of Science ®Google Scholar
• Hoshi RA, Van Lith R, Jen MC, et al. The blood and vascular cell compatibility of heparin-modified ePTFE vascular grafts. Biomaterials. 2013;34(1):30–41. DOI:https://doi.org/10.1016/j.biomaterials.2012.09.046.
   PubMed Web of Science ®Google Scholar
• Nie C, Ma L, Cheng C, et al. Nanofibrous heparin and heparin-mimicking multilayers as highly effective endothelialization and antithrombogenic coatings. Biomacromolecules. 2015;16(3):992–1001. DOI:https://doi.org/10.1021/bm501882b.
   PubMed Web of Science ®Google Scholar
• Kim H,Park, H, Lee, J.W, et al. Magnetic field-responsive release of transforming growth factor beta 1 from heparin-modified alginate ferrogels. Carbohydr Polym. 2016;151:467–473.
   PubMed Web of Science ®Google Scholar
• Mei L, Liu Y, Zhang H, et al. Antitumor and antimetastasis activities of heparin-based micelle served as both carrier and drug. ACS Appl Mater Interfaces. 2016;8(15):9577–9589. DOI:https://doi.org/10.1021/acsami.5b12347.
   PubMed Web of Science ®Google Scholar
• Zhang F, Fei J, Sun M, et al. Heparin modification enhances the delivery and tumor targeting of paclitaxel-loaded N-octyl-N-trimethyl chitosan micelles. Int J Pharm. 2016;511(1):390–402. DOI:https://doi.org/10.1016/j.ijpharm.2016.07.020.
   PubMed Web of Science ®Google Scholar
• Zhang B, Yang X, Wang Y, et al. Heparin modified graphene oxide for pH-sensitive sustained release of doxorubicin hydrochloride. Mater Sci Eng C Mater Biol Appl. 2017;75:198–206. DOI:https://doi.org/10.1016/j.msec.2017.02.048
   PubMed Web of Science ®Google Scholar
• Yalpani M, Hall LD, Tung MA, et al. Unusual rheology of a branched, water-soluble chitosan derivative. Nature. 1983;302(5911):812–814. DOI:https://doi.org/10.1038/302812a0.
   Web of Science ®Google Scholar
• Ren G, Clancy C, Tamer TM, et al. Cinnamyl O-amine functionalized chitosan as a new excipient in direct compressed tablets with improved drug delivery. Int J Biol Macromol. 2019;141:936–946.
   PubMed Web of Science ®Google Scholar
• Lv Y, Yang B, Jiang T, et al. Folate-conjugated amphiphilic block copolymers for targeted and efficient delivery of doxorubicin. Colloids Surf B Biointerfaces. 2014;115:253–259.
   PubMed Web of Science ®Google Scholar
• Chen C, Ke J, Zhou XE, et al. Structural basis for molecular recognition of folic acid by folate receptors. Nature. 2013;500(7463):486–489. DOI:https://doi.org/10.1038/nature12327.
   PubMed Web of Science ®Google Scholar
• Anirudhan TS, Chithra Sekhar V, Athira VS. Graphene oxide based functionalized chitosan polyelectrolyte nanocomposite for targeted and pH responsive drug delivery. Int J Biol Macromol. 2020;150:468–479.
   PubMed Web of Science ®Google Scholar
• Pazoki-Toroudi H, Nassiri-Kashani M, Tabatabaie H, et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. J Dermatological Treat. 2010;21(3):212–216. DOI:https://doi.org/10.3109/09546630903440064.
   PubMed Web of Science ®Google Scholar
• Langer R, Chasin M. Biodegradable polymers as drug delivery systems. Inf Health Care. 1990.
   Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818–1822.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18.
   PubMed Web of Science ®Google Scholar
• Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev. 2009;61(13):1177–1188.
   PubMed Web of Science ®Google Scholar
• Sezgin Z, Yüksel N, Baykara T. Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. Eur J Pharm Biopharm. 2006;64(3):261–268.
   PubMed Web of Science ®Google Scholar
• Kazempour M,Namazi, H, Akbarzadeh, A, et al. Synthesis and characterization of PEG-functionalized graphene oxide as an effective pH-sensitive drug carrier. Artif Cells Nanomed Biotechnol. 47(1): 90–94. 2019. . https://doi.org/10.1080/21691401.2018.1543196.
   PubMed Web of Science ®Google Scholar
• Li D, Zhang R, Liu G, et al. Redox‐Responsive Self‐Assembled Nanoparticles for Cancer Therapy. Adv Healthc Mater. 2020;9(20):2000605. DOI:https://doi.org/10.1002/adhm.202000605.
   Web of Science ®Google Scholar
• Kirtonia A, Sethi G, Garg M. The multifaceted role of reactive oxygen species in tumorigenesis. Cell Mol Life Sci. 2020;77(22):4459–4483.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim C, Lee S-G, et al. Ophiopogonin D, a steroidal glycoside abrogates STAT3 signaling cascade and exhibits anti-cancer activity by causing gsh/gssg imbalance in lung carcinoma. Cancers (Basel). 2018;10(11):427. DOI:https://doi.org/10.3390/cancers10110427.
   Web of Science ®Google Scholar
• Li F,Shanmugam, M.K, Chen, L, et al. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. Cancer Prev Res (Phila). 2013;6(8):843–854. DOI:https://doi.org/10.1158/1940-6207.CAPR-13-0070.
   PubMed Web of Science ®Google Scholar
• Ruan C, Liu L, Wang Q, et al. Reactive oxygen species-biodegradable gene carrier for the targeting therapy of breast cancer. ACS Appl Mater Interfaces. 2018;10(12):10398–10408. DOI:https://doi.org/10.1021/acsami.8b01712.
   PubMed Web of Science ®Google Scholar
• Chuan X, Song Q, Lin J, et al. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly (ethylene glycol)–drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo. Mol Pharm. 2014;11(10):3656–3670. DOI:https://doi.org/10.1021/mp500399j.
   PubMed Web of Science ®Google Scholar
• Ma N, Song A, Li Z, et al. Redox-sensitive prodrug molecules meet graphene oxide: an efficient graphene oxide-based nanovehicle toward cancer therapy. ACS Biomater Sci Eng. 2019;5(3):1384–1391. DOI:https://doi.org/10.1021/acsbiomaterials.9b00114.
   PubMed Web of Science ®Google Scholar
• Wen H, Dong C, Dong H, et al. Engineered redox-responsive PEG detachment mechanism in PEGylated nano-graphene oxide for intracellular drug delivery. Small. 2012;8(5):760–769. DOI:https://doi.org/10.1002/smll.201101613.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang Z, Zong S, et al. SERS-fluorescence monitored drug release of a redox-responsive nanocarrier based on graphene oxide in tumor cells. ACS Appl Mater Interfaces. 2014;6(20):17526–17533. DOI:https://doi.org/10.1021/am505160v.
   PubMed Web of Science ®Google Scholar
• Hu Q, Katti PS, Gu Z. Enzyme-responsive nanomaterials for controlled drug delivery. Nanoscale. 2014;6(21):12273–12286.
   PubMed Web of Science ®Google Scholar
• Li X, Burger S, O’Connor AJ, et al. An enzyme-responsive controlled release system based on a dual-functional peptide. Chem Comm. 2016;52(29):5112–5115. DOI:https://doi.org/10.1039/C5CC10480G.
   PubMed Web of Science ®Google Scholar
• Callmann CE, Barback CV, Thompson MP, et al. Therapeutic enzyme‐responsive nanoparticles for targeted delivery and accumulation in tumors. Adv Mater. 2015;27(31):4611–4615. DOI:https://doi.org/10.1002/adma.201501803.
   PubMed Web of Science ®Google Scholar
• Trusek A, Kijak E, Granicka L. Graphene oxide as a potential drug carrier - Chemical carrier activation, drug attachment and its enzymatic controlled release. Mater Sci Eng C Mater Biol Appl. 2020;116:111240.
   PubMed Web of Science ®Google Scholar
• Wang Y, Deng Y, Luo H, et al. Light-responsive nanoparticles for highly efficient cytoplasmic delivery of anticancer agents. ACS nano. 2017;11(12):12134–12144. DOI:https://doi.org/10.1021/acsnano.7b05214.
   PubMed Web of Science ®Google Scholar
• Díaz-Moscoso A, Ballester P. Light-responsive molecular containers. Chem Comm. 2017;53(34):4635–4652.
   PubMed Web of Science ®Google Scholar
• Jia S, Fong W-K, Graham B, et al. Photoswitchable molecules in long-wavelength light-responsive drug delivery: from molecular design to applications. Chem Mater. 2018;30(9):2873–2887. DOI:https://doi.org/10.1021/acs.chemmater.8b00357.
   Web of Science ®Google Scholar
• Kurapati R, Raichur AM. Near-infrared light-responsive graphene oxide composite multilayer capsules: a novel route for remote controlled drug delivery. Chem Commun (Camb). 2013;49(7):734–736.
   PubMed Web of Science ®Google Scholar
• Jiang W, Mo F, Lin Y, et al. Tumor targeting dual stimuli responsive controllable release nanoplatform based on DNA-conjugated reduced graphene oxide for chemo-photothermal synergetic cancer therapy. J Mater Chem B. 2018;6(26):4360–4367. DOI:https://doi.org/10.1039/C8TB00670A.
   PubMed Web of Science ®Google Scholar
• Carlström KE, Zhu K, Ewing E, et al. Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis. Nat Commun. 2020;11(1):4071. DOI:https://doi.org/10.1038/s41467-020-17871-5.
   PubMed Web of Science ®Google Scholar
• Shteinfer-Kuzmine A, Verma A, Arif T, et al. Mitochondria and nucleus cross-talk: signaling in metabolism, apoptosis, and differentiation, and function in cancer. IUBMB Life. 2020;73:492–510.
   PubMed Web of Science ®Google Scholar
• Do BH, Nguyen TPT, Ho NQC, et al. Mitochondria-mediated caspase-dependent and caspase-independent apoptosis induced by aqueous extract from moringa oleifera leaves in human melanoma cells. Mol Biol Rep. 2020;47(5):3675–3689. DOI:https://doi.org/10.1007/s11033-020-05462-y.
   PubMed Web of Science ®Google Scholar
• Mohan CD,Rangappa, S, Preetham, H.D, et al. Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature. Semin Cancer Biol. 2020. DOI:https://doi.org/10.1016/j.semcancer.2020.03.016.
   Google Scholar
• Kim SM, Kim C, Bae H, et al. 6-Shogaol exerts anti-proliferative and pro-apoptotic effects through the modulation of STAT3 and MAPKs signaling pathways. Mol Carcinog. 2015;54(10):1132–1146. DOI:https://doi.org/10.1002/mc.22184.
   PubMed Web of Science ®Google Scholar
• Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015;14(2):111–129.
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79(3):629–661.
   PubMed Web of Science ®Google Scholar
• Deng S, Shanmugam MK, Kumar AP, et al. Targeting autophagy using natural compounds for cancer prevention and therapy. Cancer. 2019;125(8):1228–1246. DOI:https://doi.org/10.1002/cncr.31978.
   PubMed Web of Science ®Google Scholar
• Shanmugam MK, Ong TH, Kumar AP, et al. Ursolic acid inhibits the initiation, progression of prostate cancer and prolongs the survival of TRAMP mice by modulating pro-inflammatory pathways. PLoS One. 2012;7(3):e32476. DOI:https://doi.org/10.1371/journal.pone.0032476.
   PubMed Web of Science ®Google Scholar
• Kim C, Cho SK, Kapoor S, et al. β-Caryophyllene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase. Mol Carcinog. 2014;53(10):793–806. DOI:https://doi.org/10.1002/mc.22035.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu Z, Zheng Y, et al. Glycyrrhetinic acid functionalized graphene oxide for mitochondria targeting and cancer treatment in vivo. Small. 14(4): 1703306. 2018. . https://doi.org/10.1002/smll.201703306.
   Web of Science ®Google Scholar
• Praharaj PP, Naik PP, Panigrahi DP, et al. Intricate role of mitochondrial lipid in mitophagy and mitochondrial apoptosis: its implication in cancer therapeutics. Cell Mol Life Sci. 2019;76(9):1641–1652. DOI:https://doi.org/10.1007/s00018-018-2990-x.
   PubMed Web of Science ®Google Scholar
• Tewari D, Nabavi SF, Nabavi SM, et al Targeting activator protein 1 signaling pathway by bioactive natural agents: possible therapeutic strategy for cancer prevention and intervention. Pharmacol Res. 2018;128:366–375.
   PubMed Web of Science ®Google Scholar
• Mishra S, Verma SS, Rai V, et al. Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases. Cell Mol Life Sci. 2019;76(10):1947–1966. DOI:https://doi.org/10.1007/s00018-019-03053-0.
   PubMed Web of Science ®Google Scholar
• Barras A, Boussekey L, Courtade E, et al. Hypericin-loaded lipid nanocapsules for photodynamic cancer therapy in vitro. Nanoscale. 2013;5(21):10562–10572. DOI:https://doi.org/10.1039/c3nr02724d.
   PubMed Web of Science ®Google Scholar
• Sureau F, Miskovsky P, Chinsky L, et al. Hypericin-induced cell photosensitization involves an intracellular pH decrease. J Am Chem Soc. 1996;118(40):9484–9487. DOI:https://doi.org/10.1021/ja961783k.
   Web of Science ®Google Scholar
• Cona MM, Feng Y, Zhang J, et al. Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction. Drug Deliv. 2015;22(3):427–435. DOI:https://doi.org/10.3109/10717544.2013.873838.
   PubMed Web of Science ®Google Scholar
• Zhang Q,Li, Y.Y, Shi, S.J, et al. Hypericin-photodynamic therapy induces human umbilical vein endothelial cell apoptosis. Sci Rep. 2015;5(1):1–13. DOI:https://doi.org/10.1038/srep18398.
   Web of Science ®Google Scholar
• Lima AM, Pizzol CD, Monteiro FBF, et al. Hypericin encapsulated in solid lipid nanoparticles: phototoxicity and photodynamic efficiency. J Photochem Photobiol B Biol. 2013;125:146–154.
   PubMed Web of Science ®Google Scholar
• Siboni G, Amit-Patito, I, Weizman, E, et al. Specificity of photosensitizer accumulation in undifferentiated versus differentiated colon carcinoma cells. Cancer Lett. 2003;196(1):57–64. DOI:https://doi.org/10.1016/S0304-3835(03)00207-6.
   PubMed Web of Science ®Google Scholar
• Han C, Zhang C, Ma T, et al. Hypericin-functionalized graphene oxide for enhanced mitochondria-targeting and synergistic anticancer effect. Acta Biomater. 2018;77:268–281.
   PubMed Web of Science ®Google Scholar
• Motoyama K, Mitsuyasu R, Akao C, et al. Potential use of thioalkylated mannose-modified dendrimer (G3)/α-cyclodextrin conjugate as an NF-κB siRNA carrier for the treatment of fulminant hepatitis. Mol Pharm. 2015;12(9):3129–3136. DOI:https://doi.org/10.1021/mp500814f.
   PubMed Web of Science ®Google Scholar
• Ketkar-Atre A, Struys T, Dresselaers T, et al. In vivo hepatocyte MR imaging using lactose functionalized magnetoliposomes. Biomaterials. 2014;35(3):1015–1024. DOI:https://doi.org/10.1016/j.biomaterials.2013.10.029.
   PubMed Web of Science ®Google Scholar
• Chen Y, Minh LV, Liu J, et al. Baicalin loaded in folate-PEG modified liposomes for enhanced stability and tumor targeting. Colloids Surf B Biointerfaces. 2016;140:74–82.
   PubMed Web of Science ®Google Scholar
• Pourjavadi A, Tehrani ZM, Moghanaki AA. Folate-conjugated pH-responsive nanocarrier designed for active tumor targeting and controlled release of gemcitabine. Pharm Res. 2016;33(2):417–432.
   PubMed Web of Science ®Google Scholar
• Jain NK, Chaurasia M, Jain S. Investigation of galactosylated low molecular weight chitosan-coated liposomes for cancer specific drug delivery. Trop J Pharm Res. 2014;13(5):661–668.
   Web of Science ®Google Scholar
• Kim SE, Yun Y-P, Shim K-S, et al. Fabrication of a BMP-2-immobilized porous microsphere modified by heparin for bone tissue engineering. Colloids and Surfaces B. Biointerfaces. 2015;134:453–460.
   PubMed Web of Science ®Google Scholar
• Shang Y,Tamai, M, Ishii, R, et al. Hybrid sponge comprised of galactosylated chitosan and hyaluronic acid mediates the co-culture of hepatocytes and endothelial cells. J Biosci Bioeng. 2014;117(1):99–106. DOI:https://doi.org/10.1016/j.jbiosc.2013.06.015.
   PubMed Web of Science ®Google Scholar
• Zhu XL, Du Y, Yu R, et al. Galactosylated chitosan oligosaccharide nanoparticles for hepatocellular carcinoma cell-targeted delivery of adenosine triphosphate. Int J Mol Sci. 2013;14(8):15755–15766. DOI:https://doi.org/10.3390/ijms140815755.
   PubMed Web of Science ®Google Scholar
• Yu J-M, Li W-D, Lu L, et al. Preparation and characterization of galactosylated glycol chitosan micelles and its potential use for hepatoma-targeting delivery of doxorubicin. J Mater Sci. 2014;25(3):691–701. DOI:https://doi.org/10.1007/s10856-013-5109-9.
   Web of Science ®Google Scholar
• Villa R, Cerroni B, Viganò L, et al. Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells. Colloids and Surfaces B. Biointerfaces. 2013;110:434–442.
   PubMed Web of Science ®Google Scholar
• Zuo H, Gu Z, Cooper H, et al. Crosslinking to enhance colloidal stability and redispersity of layered double hydroxide nanoparticles. J Colloid Interface Sci. 2015;459:10–16.
   PubMed Web of Science ®Google Scholar
• Tóth IY, Nesztor D, Novák L, et al. Clustering of carboxylated magnetite nanoparticles through polyethylenimine: covalent versus electrostatic approach. J Magn Magn Mater. 2017;427:280–288.
   Web of Science ®Google Scholar
• Pavlovic M, Rouster P, Szilagyi I. Synthesis and formulation of functional bionanomaterials with superoxide dismutase activity. Nanoscale. 2017;9(1):369–379.
   PubMed Web of Science ®Google Scholar
• Dehshahri A, Ashrafizadeh M, Ghasemipour Afshar E, et al. Topoisomerase inhibitors: pharmacology and emerging nanoscale delivery systems. Pharmacol Res. 2020;151:104551.
   PubMed Web of Science ®Google Scholar
• Moballegh Nasery M, Abadi B, Poormoghadam D, et al. Curcumin delivery mediated by bio-based nanoparticles: a review. Molecules. 2020;25(3):689. DOI:https://doi.org/10.3390/molecules25030689.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Ahmadi Z, Kotla NG, et al. Nanoparticles Targeting STATs in Cancer Therapy. Cells. 2019;8(10):1158. DOI:https://doi.org/10.3390/cells8101158.
   PubMed Web of Science ®Google Scholar
• Aggarwal V, Tuli HS, Thakral F, et al. Molecular mechanisms of action of hesperidin in cancer: recent trends and advancements. Exp Biol Med (Maywood). 2020;245(5):486–497. DOI:https://doi.org/10.1177/1535370220903671.
   PubMed Web of Science ®Google Scholar
• Tang Z-X, Qian J-Q, Shi L-E. Characterizations of immobilized neutral lipase on chitosan nano-particles. Mater Lett. 2007;61(1):37–40.
   Web of Science ®Google Scholar
• Wang C, Zhang Z, Chen B, et al. Design and evaluation of galactosylated chitosan/graphene oxide nanoparticles as a drug delivery system. J Colloid Interface Sci. 2018;516:332–341.
   PubMed Web of Science ®Google Scholar
• Bhuvanalakshmi G, Gamit N, Patil M, et al. Stemness, pluripotentiality, and wnt antagonism: sfrp4, a wnt antagonist mediates pluripotency and stemness in glioblastoma. Cancers (Basel). 2018;11(1):25. DOI:https://doi.org/10.3390/cancers11010025.
   Web of Science ®Google Scholar
• Mostafavi E,Medina-Cruz, D, Vernet-Crua, A, et al. Green nanomedicine: the path to the next generation of nanomaterials for diagnosing brain tumors and therapeutics? Expert Opin Drug Deliv. 2021;18(6):715–736.
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng X, Gong M, et al. Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma. Oncotarget. 2016;7(48):79401–79407. DOI:https://doi.org/10.18632/oncotarget.12708.
   PubMedGoogle Scholar
• Hsu SP, Dhawan U, Tseng -Y-Y, et al. Glioma-sensitive delivery of Angiopep-2 conjugated iron gold alloy nanoparticles ensuring simultaneous tumor imaging and hyperthermia mediated cancer theranostics. Appl Mater Today. 2020;18:100510.
   Web of Science ®Google Scholar
• Lu F,Pang, Z, Zhao, J, et al. Angiopep-2-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. Int J Nanomedicine. 2017;38:2117–2127.
   Web of Science ®Google Scholar
• Zhao Y, Yin H, Zhang X. Modification of graphene oxide by angiopep-2 enhances anti-glioma efficiency of the nanoscaled delivery system for doxorubicin. Aging (Albany NY). 2020;12(11):10506–10516.
   PubMedGoogle Scholar
• Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and Clinical Implications. Cancer. 1994;73(9):2432–2443.
   Google Scholar
• Tyagi A, Penzkofer A. Fluorescence spectroscopic behaviour of folic acid. Chem Phys. 2010;367(2–3):83–92.
   Web of Science ®Google Scholar
• Diaz-Diestra D, Thapa B, Badillo-Diaz D, et al. Graphene Oxide/ZnS:Mn nanocomposite functionalized with folic acid as a nontoxic and effective theranostic platform for breast cancer treatment. Nanomaterials (Basel). 2018;8(7):484. DOI:https://doi.org/10.3390/nano8070484.
   Google Scholar
• Liu Z, Liu J, Wang T, et al. Switching off the interactions between graphene oxide and doxorubicin using vitamin C: combining simplicity and efficiency in drug delivery. J Mater Chem B. 2018;6(8):1251–1259. DOI:https://doi.org/10.1039/C7TB03063K.
   PubMed Web of Science ®Google Scholar
• Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007;59(7):645–666.
   PubMed Web of Science ®Google Scholar
• Li J, Loh XJ. Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv Drug Deliv Rev. 2008;60(9):1000–1017.
   PubMed Web of Science ®Google Scholar
• Li X, Imae T, Leisner D, et al. Lamellar structures of anionic poly (amido amine) dendrimers with oppositely charged didodecyldimethylammonium bromide. J Phys Chem A. 2002;106(47):12170–12177. DOI:https://doi.org/10.1021/jp020926o.
   Web of Science ®Google Scholar
• Tiriveedhi V, Kitchens KM, Nevels KJ, et al. Kinetic analysis of the interaction between poly (amidoamine) dendrimers and model lipid membranes. Biochimi Biophys Acta (BBA) Biomembr. 2011;1808(1):209–218. DOI:https://doi.org/10.1016/j.bbamem.2010.08.017.
   PubMed Web of Science ®Google Scholar
• Siriviriyanun A,Tsai, Y.J, Voon, S.H, et al. Cyclodextrin- and dendrimer-conjugated graphene oxide as a nanocarrier for the delivery of selected chemotherapeutic and photosensitizing agents. Mater Sci Eng C Mater Biol Appl. 2018;89:307–315.
   PubMed Web of Science ®Google Scholar
• Mahdavi M, Fattahi A, Tajkhorshid E, et al. Molecular insights into the loading and dynamics of doxorubicin on pegylated graphene oxide nanocarriers. ACS Appl Bio Mater. 2020;3(3):1354–1363. DOI:https://doi.org/10.1021/acsabm.9b00956.
   PubMedGoogle Scholar
• Zhang J, Chen L, Shen B, et al. Dual-sensitive graphene oxide loaded with proapoptotic peptides and anticancer drugs for cancer synergetic therapy. Langmuir. 2019;35(18):6120–6128. DOI:https://doi.org/10.1021/acs.langmuir.9b00611.
   PubMed Web of Science ®Google Scholar
• Nanda SS, Papaefthymiou GC, Yi DK. Functionalization of graphene oxide and its biomedical applications. Critl Rev Solid State Mater Sci. 2015;40(5):291–315.
   Web of Science ®Google Scholar
• Yang K, Feng L, Hong H, et al. Preparation and functionalization of graphene nanocomposites for biomedical applications. Nat Protoc. 2013;8(12):2392–2403. DOI:https://doi.org/10.1038/nprot.2013.146.
   PubMed Web of Science ®Google Scholar
• Xie M, Lei H, Zhang Y, et al. Non-covalent modification of graphene oxide nanocomposites with chitosan/dextran and its application in drug delivery. RSC Adv. 2016;6(11):9328–9337. DOI:https://doi.org/10.1039/C5RA23823D.
   Web of Science ®Google Scholar
• Lei H, Xie M, Zhao Y, et al. Chitosan/sodium alginate modificated graphene oxide-based nanocomposite as a carrier for drug delivery. Ceram Int. 2016;42(15):17798–17805. DOI:https://doi.org/10.1016/j.ceramint.2016.08.108.
   Web of Science ®Google Scholar
• Xie M, Zhang F, Liu L, et al. Surface modification of graphene oxide nanosheets by protamine sulfate/sodium alginate for anti-cancer drug delivery application. Appl Surf Sci. 2018;440:853–860.
   Web of Science ®Google Scholar
• Xie M, Zhang F, Peng H, et al. Layer-by-layer modification of magnetic graphene oxide by chitosan and sodium alginate with enhanced dispersibility for targeted drug delivery and photothermal therapy. Colloids Surf B Biointerfaces. 2019;176:462–470.
   PubMed Web of Science ®Google Scholar
• Zhan C, Gu B, Xie C, et al. Cyclic RGD conjugated poly (ethylene glycol)-co-poly (lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release. 2010;143(1):136–142. DOI:https://doi.org/10.1016/j.jconrel.2009.12.020.
   PubMed Web of Science ®Google Scholar
• Xiong X-B, Mahmud A, Uludaǧ H, et al. Conjugation of arginine-glycine-aspartic acid peptides to Poly(ethylene oxide)- b -poly(ε-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. Biomacromolecules. 2007;8(3):874–884. DOI:https://doi.org/10.1021/bm060967g.
   PubMed Web of Science ®Google Scholar
• Tian H,Lin, L, Chen, J, et al. RGD targeting hyaluronic acid coating system for PEI-PBLG polycation gene carriers. J Control Release. 2011;155(1):47–53. DOI:https://doi.org/10.1016/j.jconrel.2011.01.025.
   PubMed Web of Science ®Google Scholar
• Wang C, Chen B, Zou M, et al. Cyclic RGD-modified chitosan/graphene oxide polymers for drug delivery and cellular imaging. Colloids Surf B Biointerfaces. 2014;122:332–340.
   PubMed Web of Science ®Google Scholar
• Liang W, Huang Y, Lu D, et al. β-Cyclodextrin⁻hyaluronic acid polymer functionalized magnetic graphene oxide nanocomposites for targeted photo-chemotherapy of tumor cells. Polymers (Basel). 2019;11(1):133. DOI:https://doi.org/10.3390/polym11010133.
   Web of Science ®Google Scholar
• Lei Y, Hamada Y, Li J, et al. Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression. J Control Release. 2016;232:131–142.
   PubMed Web of Science ®Google Scholar
• Gomme PT, McCann KB, Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today. 2005;10(4):267–273.
   PubMed Web of Science ®Google Scholar
• Wei Y, Gu X, Cheng L, et al. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. Acta Biomater. 2019;92:196–204.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu T, Liu X, et al. Preparation of paclitaxel-folic acid functionalized gelatin grafted mesoporous hollow carbon nanospheres for enhancing antitumor effects toward liver cancer (SMMC-7721) cell lines. J Biomater Appl. 2020;34(8):1071–1080. DOI:https://doi.org/10.1177/0885328219896457.
   PubMed Web of Science ®Google Scholar
• Lu T, Nong Z, Wei L, et al. Preparation and anti-cancer activity of transferrin/folic acid double-targeted graphene oxide drug delivery system. J Biomater Appl. 2020;35(1):15–27. DOI:https://doi.org/10.1177/0885328220913976.
   PubMed Web of Science ®Google Scholar
• Pooresmaeil M, Namazi H. Surface modification of graphene oxide with stimuli-responsive polymer brush containing β-cyclodextrin as a pendant group: preparation, characterization, and evaluation as controlled drug delivery agent. Colloids Surf B Biointerfaces. 2018;172:17–25.
   PubMed Web of Science ®Google Scholar
• Song E, Han W, Li C, et al. Hyaluronic acid-decorated graphene oxide nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery. ACS Appl Mater Interfaces. 2014;6(15):11882–11890. DOI:https://doi.org/10.1021/am502423r.
   PubMed Web of Science ®Google Scholar
• Roy S, Sarkar A, Jaiswal A. Poly(allylamine hydrochloride)-functionalized reduced graphene oxide for synergistic chemo-photothermal therapy. Nanomedicine (Lond). 2019;14(3):255–274.
   PubMed Web of Science ®Google Scholar
• Chauhan G, Chopra V, Tyagi A, et al. “Gold nanoparticles composite-folic acid conjugated graphene oxide nanohybrids” for targeted chemo-thermal cancer ablation: in vitro screening and in vivo studies. Eur J Pharm Sci. 2017;96:351–361.
   PubMed Web of Science ®Google Scholar
• Wei G, Yan M, Dong R, et al. Covalent modification of reduced graphene oxide by means of diazonium chemistry and use as a drug-delivery system. Chemistry. 2012;18(46):14708–14716. DOI:https://doi.org/10.1002/chem.201200843.
   PubMed Web of Science ®Google Scholar
• Arjmand O, Ardjmand M, Amani AM, et al. Development of A novel system based on green magnetic/graphene oxide/chitosan /allium sativum/quercus/nanocomposite for targeted release of doxorubicin anti-cancer drug. Anticancer Agents Med Chem. 2020;20(9):1094–1104. DOI:https://doi.org/10.2174/1871520620666200213105203.
   PubMed Web of Science ®Google Scholar
• Liu H, Li T, Liu Y, et al. Glucose-reduced graphene oxide with excellent biocompatibility and photothermal efficiency as well as drug loading. Nanoscale Res Lett. 2016;11(1):211. DOI:https://doi.org/10.1186/s11671-016-1423-8.
   PubMed Web of Science ®Google Scholar
• Zhang C,Liu, Z, Zheng, Y, et al. Glycyrrhetinic acid functionalized graphene oxide for mitochondria targeting and cancer treatment in vivo. Small. 2018;14(4):1703306.
   Web of Science ®Google Scholar
• Ardeshirzadeh B, Anaraki NA, Irani M, et al. Controlled release of doxorubicin from electrospun PEO/chitosan/graphene oxide nanocomposite nanofibrous scaffolds. Mater Sci Eng C Mater Biol Appl. 2015;48:384–390.
   PubMed Web of Science ®Google Scholar
• Gu Y, Guo Y, Wang C, et al. A polyamidoamne dendrimer functionalized graphene oxide for DOX and MMP-9 shRNA plasmid co-delivery. Mater Sci Eng C Mater Biol Appl. 2017;70(Pt 1):572–585. DOI:https://doi.org/10.1016/j.msec.2016.09.035.
   PubMed Web of Science ®Google Scholar
• Wang F, Sun Q, Feng B, et al. Polydopamine-functionalized graphene oxide loaded with gold nanostars and doxorubicin for combined photothermal and chemotherapy of metastatic breast cancer. Adv Healthc Mater. 2016;5(17):2227–2236. DOI:https://doi.org/10.1002/adhm.201600283.
   PubMed Web of Science ®Google Scholar
• Wang X, Hao L, Zhang C, et al. High efficient anti-cancer drug delivery systems using tea polyphenols reduced and functionalized graphene oxide. J Biomater Appl. 2017;31(8):1108–1122. DOI:https://doi.org/10.1177/0885328216689364.
   PubMed Web of Science ®Google Scholar
• Borandeh S,Abdolmaleki, A, Abolmaali, S.S, et al. Synthesis, structural and in-vitro characterization of β-cyclodextrin grafted L-phenylalanine functionalized graphene oxide nanocomposite: a versatile nanocarrier for pH-sensitive doxorubicin delivery. Carbohydr Polym, 2018. 201: p. 151–161.
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu H, Li Y, et al. Hyaluronic acid and Arg-Gly-Asp peptide modified Graphene oxide with dual receptor-targeting function for cancer therapy. J Biomater Appl. 2017;32(1):54–65. DOI:https://doi.org/10.1177/0885328217712110.
   PubMed Web of Science ®Google Scholar
• Fong YT, Chen CH, Chen JP. intratumoral delivery of doxorubicin on folate-conjugated graphene oxide by in-situ forming thermo-sensitive hydrogel for breast cancer therapy. Nanomaterials (Basel). 2017;7(11):388.
   PubMedGoogle Scholar
• Wang H, Gu W, Xiao N, et al. Chlorotoxin-conjugated graphene oxide for targeted delivery of an anticancer drug. Int J Nanomedicine. 2014;9:1433–1442.
   PubMed Web of Science ®Google Scholar
• Pan Q, Lv Y, Williams GR, et al. Lactobionic acid and carboxymethyl chitosan functionalized graphene oxide nanocomposites as targeted anticancer drug delivery systems. Carbohydr Polym. 2016;151:812–820.
   PubMed Web of Science ®Google Scholar
• Kiew SF, Ho YT, Kiew LV, et al. Preparation and characterization of an amylase-triggered dextrin-linked graphene oxide anticancer drug nanocarrier and its vascular permeability. Int J Pharm. 2017;534(1–2):297–307. DOI:https://doi.org/10.1016/j.ijpharm.2017.10.045.
   PubMed Web of Science ®Google Scholar
• Fan L, Ge H, Zou S, et al. Sodium alginate conjugated graphene oxide as a new carrier for drug delivery system. Int J Biol Macromol. 2016;93(Pt A):582–590. DOI:https://doi.org/10.1016/j.ijbiomac.2016.09.026.
   PubMed Web of Science ®Google Scholar
• Shao L, Zhang R, Lu J, et al. Mesoporous silica coated polydopamine functionalized reduced graphene oxide for synergistic targeted chemo-photothermal therapy. ACS Appl Mater Interfaces. 2017;9(2):1226–1236. DOI:https://doi.org/10.1021/acsami.6b11209.
   PubMed Web of Science ®Google Scholar
• Cao X, Zheng S, Zhang S, et al. Functionalized graphene oxide with hepatocyte targeting as anti-tumor drug and gene intracellular transporters. J Nanosci Nanotechnol. 2015;15(3):2052–2059. DOI:https://doi.org/10.1166/jnn.2015.9145.
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang L, Li X, et al. Functionalized graphene oxide nanoparticles for cancer cell-specific delivery of antitumor drug. Bioconjug Chem. 2015;26(1):128–136. DOI:https://doi.org/10.1021/bc5005137.
   PubMed Web of Science ®Google Scholar
• Miao W, Shim G, Lee S, et al. Safety and tumor tissue accumulation of pegylated graphene oxide nanosheets for co-delivery of anticancer drug and photosensitizer. Biomaterials. 2013;34(13):3402–3410. DOI:https://doi.org/10.1016/j.biomaterials.2013.01.010.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhou C, Xia J, et al. Fabrication and characterization of a triple functionalization of graphene oxide with Fe3O4, folic acid and doxorubicin as dual-targeted drug nanocarrier. Colloids Surf B Biointerfaces. 2013;106:60–65.
   PubMed Web of Science ®Google Scholar
• Li R, Wang Y, Du J, et al. Graphene oxide loaded with tumor-targeted peptide and anti-cancer drugs for cancer target therapy. Sci Rep. 2021;11(1):1725. DOI:https://doi.org/10.1038/s41598-021-81218-3.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xia J, Zhao Q, et al. Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. Small. 2010;6(4):537–544. DOI:https://doi.org/10.1002/smll.200901680.
   PubMed Web of Science ®Google Scholar
• Samadi S, Moradkhani M, Beheshti H, et al. Fabrication of chitosan/poly(lactic acid)/graphene oxide/TiO2 composite nanofibrous scaffolds for sustained delivery of doxorubicin and treatment of lung cancer. Int J Biol Macromol. 2018;110:416–424.
   PubMed Web of Science ®Google Scholar
• Gole A, Murphy CJ. Seed-mediated synthesis of gold nanorods: role of the size and nature of the seed. Chem Mater. 2004;16(19):3633–3640.
   Web of Science ®Google Scholar
• Wang K, Yang P, Guo R, et al. Photothermal performance of MFe2O4 nanoparticles. Chin Chem Lett. 2019;30(12):2013–2016. DOI:https://doi.org/10.1016/j.cclet.2019.04.005.
   Web of Science ®Google Scholar
• Huang P, Bao L, Zhang C, et al. Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials. 2011;32(36):9796–9809. DOI:https://doi.org/10.1016/j.biomaterials.2011.08.086.
   PubMed Web of Science ®Google Scholar
• Shen S, Tang H, Zhang X, et al. Targeting mesoporous silica-encapsulated gold nanorods for chemo-photothermal therapy with near-infrared radiation. Biomaterials. 2013;34(12):3150–3158. DOI:https://doi.org/10.1016/j.biomaterials.2013.01.051.
   PubMed Web of Science ®Google Scholar
• Amani H, Mostafavi E, Alebouyeh MR, et al Would colloidal gold nanocarriers present an effective diagnosis or treatment for ischemic stroke? Int J Nanomedicine. 2019;14:8013–8031.
   PubMed Web of Science ®Google Scholar
• Barabadi H,Webster, T.J, Vahidi, H, et al. Green nanotechnology-based gold nanomaterials for hepatic cancer therapeutics: a systematic review. Iran J Pharm Res. 2020;19(3):3–17. DOI:https://doi.org/10.22037/ijpr.2020.113820.14504.
   PubMed Web of Science ®Google Scholar
• Niidome T,Yamagata, M, Okamoto, Y, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release. 2006;114(3):343–347. DOI:https://doi.org/10.1016/j.jconrel.2006.06.017.
   PubMed Web of Science ®Google Scholar
• Xu C,Yang, D, Mei, L, et al. Targeting chemophotothermal therapy of hepatoma by gold nanorods/graphene oxide core/shell nanocomposites. ACS Appl Mater Interfaces. 2013;5(24):384–390. DOI:https://doi.org/10.1021/am404714w.
   Web of Science ®Google Scholar
• Thapa RK, Ku SK, Choi H-G, et al. Vibrating droplet generation to assemble zwitterion-coated gold-graphene oxide stealth nanovesicles for effective pancreatic cancer chemo-phototherapy. Nanoscale. 2018;10(4):1742–1749. DOI:https://doi.org/10.1039/C7NR07603G.
   PubMed Web of Science ®Google Scholar
• Xiong X, Liu H, Zhao Z, et al. DNA aptamer‐mediated cell targeting. Angew Chem. 2013;125(5):1512–1516. DOI:https://doi.org/10.1002/ange.201207063.
   Google Scholar
• Ferreira C, Matthews C, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumor Biol. 2006;27(6):289–301.
   PubMedGoogle Scholar
• Xiao Z, Farokhzad OC. Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. ACS nano. 2012;6(5):3670–3676.
   PubMed Web of Science ®Google Scholar
• Van Simaeys D,Turek, D, Champanhac, C, et al. Identification of cell membrane protein stress-induced phosphoprotein 1 as a potential ovarian cancer biomarker using aptamers selected by cell systematic evolution of ligands by exponential enrichment. Anal Chem. 2014;86(9):4521–4527. DOI:https://doi.org/10.1021/ac500466x.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004;64(21):7668–7672. DOI:https://doi.org/10.1158/0008-5472.CAN-04-2550.
   PubMed Web of Science ®Google Scholar
• Bagalkot V, Farokhzad, O.C, Langer, R, et al. An aptamer–doxorubicin physical conjugate as a novel targeted drug‐delivery platform. Angew Chem. 2006;45(48):8149–8152. DOI:https://doi.org/10.1002/anie.200602251.
   Google Scholar
• Khademi Z, Lavaee P, Ramezani M, et al. Co-delivery of doxorubicin and aptamer against Forkhead box M1 using chitosan-gold nanoparticles coated with nucleolin aptamer for synergistic treatment of cancer cells. Carbohydr Polym. 2020;248:116735. DOI:https://doi.org/10.1016/j.carbpol.2020.116735
   PubMed Web of Science ®Google Scholar
• Nejabat M, Eisvand F, Soltani F, et al Combination therapy using Smac peptide and doxorubicin-encapsulated MUC 1-targeted polymeric nanoparticles to sensitize cancer cells to chemotherapy: an in vitro and in vivo study. Int J Pharm. 2020;587:119650.
   PubMed Web of Science ®Google Scholar
• Wang X, HanQ, Yu N, et al. Aptamer-conjugated graphene oxide-gold nanocomposites for targeted chemo-photothermal therapy of cancer cells. J Mater Chem B. 2015;3(19):4036–4042. DOI:https://doi.org/10.1039/C5TB00134J.
   PubMed Web of Science ®Google Scholar
• Wight A, Davis M. Design and preparation of organic− inorganic hybrid catalysts. Chem Rev. 2002;102(10):3589–3614.
   PubMed Web of Science ®Google Scholar
• Hoffmann F, Cornelius M, Morell J, et al. Silica‐based mesoporous organic–inorganic hybrid materials. Angew Chem. 2006;45(20):3216–3251. DOI:https://doi.org/10.1002/anie.200503075.
   Google Scholar
• Torney F, Trewyn BG, Lin VS-Y, etal. Mesoporous silica nanoparticles deliver DNA and chemicals into plants. Nat Nanotechnol. 2007;2(5):295–300. DOI:https://doi.org/10.1038/nnano.2007.108.
   PubMed Web of Science ®Google Scholar
• Sun X, Zhao Y, Lin VS-Y, et al. Luciferase and luciferin co-immobilized mesoporous silica nanoparticle materials for intracellular biocatalysis. J Am Chem Soc. 2011;133(46):18554–18557. DOI:https://doi.org/10.1021/ja2080168.
   PubMed Web of Science ®Google Scholar
• Hernandez R, Tseng H-R, Wong JW, et al. An operational supramolecular nanovalve. J Am Chem Soc. 2004;126(11):3370–3371. DOI:https://doi.org/10.1021/ja039424u.
   PubMed Web of Science ®Google Scholar
• Nguyen TD, Leung K -F, Liong M, et al. Versatile supramolecular nanovalves reconfigured for light activation. Adv Funct Mater. 2007;17(13):2101–2110. DOI:https://doi.org/10.1002/adfm.200600751.
   Web of Science ®Google Scholar
• Mal NK, Fujiwara M, Tanaka Y. Photocontrolled reversible release of guest molecules from coumarin-modified mesoporous silica. Nature. 2003;421(6921):350–353.
   PubMed Web of Science ®Google Scholar
• He D, He X, Wang K, et al. A light-responsive reversible molecule-gated system using thymine-modified mesoporous silica nanoparticles. Langmuir. 2012;28(8):4003–4008. DOI:https://doi.org/10.1021/la2047504.
   PubMed Web of Science ®Google Scholar
• Liu R, Zhao X, Wu T, et al. Tunable redox-responsive hybrid nanogated ensembles. J Am Chem Soc. 2008;130(44):14418–14419. DOI:https://doi.org/10.1021/ja8060886.
   PubMed Web of Science ®Google Scholar
• Burress JW, Gadipelli S, Ford J, et al. Graphene oxide framework materials: theoretical predictions and experimental results. Angew Chem. 2010;49(47):8902–8904. DOI:https://doi.org/10.1002/anie.201003328.
   Google Scholar
• Severin K. Boronic acids as building blocks for molecular nanostructures and polymeric materials. Dalton Trans. 2009;27:5254–5264. DOI:https://doi.org/10.1039/b902849h
   Google Scholar
• He D, He X, Wang K, et al. Remote-controlled drug release from graphene oxide-capped mesoporous silica to cancer cells by photoinduced pH-jump activation. Langmuir. 2014;30(24):7182–7189. DOI:https://doi.org/10.1021/la501075c.
   PubMed Web of Science ®Google Scholar
• Wang TT, Lan J, Zhang Y, et al. Reduced graphene oxide gated mesoporous silica nanoparticles as a versatile chemo-photothermal therapy system through pH controllable release. J Mater Chem B. 2015;3(30):6377–6384. DOI:https://doi.org/10.1039/C5TB00824G.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang X, Zhou L, et al. Reduced graphene oxide (rGO) hybridized hydrogel as a near-infrared (NIR)/pH dual-responsive platform for combined chemo-photothermal therapy. J Colloid Interface Sci. 2019;536:160–170.
   PubMed Web of Science ®Google Scholar
• Bardajee GR, Hooshyar Z, Farsi M, et al. Synthesis of a novel thermo/pH sensitive nanogel based on salep modified graphene oxide for drug release. Mater Sci Eng C Mater Biol Appl. 2017;72:558–565.
   PubMed Web of Science ®Google Scholar
• Guo L, Hao Y-W, Li P-L, et al. Improved NO(2) gas sensing properties of graphene oxide reduced by two-beam-laser interference. Sci Rep. 2018;8(1):4918. DOI:https://doi.org/10.1038/s41598-018-23091-1.
   PubMed Web of Science ®Google Scholar
• Huang A, Li W, Shi S, et al Quantitative SING. Sci Rep. 2017;7:40772.
   PubMed Web of Science ®Google Scholar
• Singh R, Hong S, Jang J. Label-free detection of influenza viruses using a reduced graphene oxide-based electrochemical immunosensor integrated with a microfluidic platform. Sci Rep. 2017;7:42771.
   PubMed Web of Science ®Google Scholar
• Cazier H,Malgorn, C, Fresneau, N, et al. Development of a mass spectrometry imaging method for detecting and mapping graphene oxide nanoparticles in rodent tissues. J Am Soc Mass Spectrom. 2020;31(5):1025–1036. DOI:https://doi.org/10.1021/jasms.9b00070.
   PubMed Web of Science ®Google Scholar
• Sethi J, Van Bulck M, Suhail A, et al. A label-free biosensor based on graphene and reduced graphene oxide dual-layer for electrochemical determination of beta-amyloid biomarkers. Mikrochim Acta. 2020;187(5):288. DOI:https://doi.org/10.1007/s00604-020-04267-x.
   PubMed Web of Science ®Google Scholar
• Ahmad T,Rhee, I, Hong, S, et al. Ni-Fe2O4 nanoparticles as contrast agents for magnetic resonance imaging. J Nanosci Nanotechnol. 2011;11(7):3589–3614. DOI:https://doi.org/10.1166/jnn.2011.4502.
   Web of Science ®Google Scholar
• Seabra AB,Paula, A.J, de Lima, R, et al. Nanotoxicity of graphene and graphene oxide. Chem Res Toxicol. 2014;27(2):4003–4008. DOI:https://doi.org/10.1021/tx400385x.
   Web of Science ®Google Scholar
• Campbell E, Hasan MT, Pho C, et al. Graphene oxide as a multifunctional platform for intracellular delivery, imaging, and cancer sensing. Sci Rep. 2019;9(1):1–9. DOI:https://doi.org/10.1038/s41598-018-36617-4.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rodriguez R, Campbell E, Naumov A. Multifunctional graphene oxide/iron oxide nanoparticles for magnetic targeted drug delivery dual magnetic resonance/fluorescence imaging and cancer sensing. PLoS One. 2019;14(6):e0217072.
   PubMed Web of Science ®Google Scholar
• Chen ML,Paula, A.J, de Lima, R, et al. In situ growth of β-FeOOH nanorods on graphene oxide with ultra-high relaxivity for in vivo magnetic resonance imaging and cancer therapy. J Mater Chem B. 2013;1(20):2582–2589. DOI:https://doi.org/10.1039/c3tb20234h.
   PubMed Web of Science ®Google Scholar
• Zhang M, Cao Y, Chong Y, et al. Graphene oxide based theranostic platform for t 1 -weighted magnetic resonance imaging and drug delivery. ACS Appl Mater Interfaces. 2013;5(24):13325–13332. DOI:https://doi.org/10.1021/am404292e.
   PubMed Web of Science ®Google Scholar
• Shen AJ, Li D-L, Cai X-J, et al. Multifunctional nanocomposite based on graphene oxide for in vitro hepatocarcinoma diagnosis and treatment. J Biomed Mater Res A. 2012;100(9):2499–2506. DOI:https://doi.org/10.1002/jbm.a.34148.
   PubMed Web of Science ®Google Scholar
• Sun X, Liu Z, Welsher K, et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res. 2008;1(3):203–212. DOI:https://doi.org/10.1007/s12274-008-8021-8.
   PubMed Web of Science ®Google Scholar
• Ma X, Qu Q, Zhao Y, et al. Graphene oxide wrapped gold nanoparticles for intracellular Raman imaging and drug delivery. J Mater Chem B. 2013;1(47):6495–6500. DOI:https://doi.org/10.1039/c3tb21385d.
   PubMed Web of Science ®Google Scholar
• Kundu A, Nandi S, Das P, et al. Fluorescent graphene oxide via polymer grafting: an efficient nanocarrier for both hydrophilic and hydrophobic drugs. ACS Appl Mater Interfaces. 2015;7(6):3512–3523. DOI:https://doi.org/10.1021/am507110r.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zou X, Zhao JX, et al Graphene oxide-based magnetic fluorescent hybrids for drug delivery and cellular imaging. Colloids Surf B Biointerfaces. 2013;112:128–133.
   PubMed Web of Science ®Google Scholar
• Huang C, Hu X, Hou Z, et al Tailored graphene oxide-doxorubicin nanovehicles via near-infrared dye-lactobionic acid conjugates for chemo-photothermal therapy. J Colloid Interface Sci. 2019;545:172–183.
   PubMed Web of Science ®Google Scholar
• Sailo BL, Banik K, Girisa S, et al. FBXW7 in cancer: what has been unraveled thus far? Cancers (Basel). 2019;11(2):246. DOI:https://doi.org/10.3390/cancers11020246.
   Web of Science ®Google Scholar
• Raghunath A, Sundarraj K, Arfuso F, et al. Dysregulation of Nrf2 in hepatocellular carcinoma: role in cancer progression and chemoresistance. Cancers (Basel). 2018;10(12):481. DOI:https://doi.org/10.3390/cancers10120481.
   PubMed Web of Science ®Google Scholar
• Li F, Shanmugam MK, Siveen KS, et al. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. Oncotarget. 2015;6(7):5147–5163. DOI:https://doi.org/10.18632/oncotarget.2881.
   PubMedGoogle Scholar
• Monisha J,Roy, N.K, Padmavathi, G, et al. NGAL is downregulated in oral squamous cell carcinoma and leads to increased survival, proliferation. Migration and Chemoresistance. Cancers (Basel). 2018;10(7):228.
   Web of Science ®Google Scholar
• Makvandi P, Ghomi M, Ashrafizadeh M, et al. A review on advances in graphene-derivative/polysaccharide bionanocomposites: therapeutics, pharmacogenomics and toxicity. Carbohydr Polym. 2020;250:116952.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Sriram P, Barui AK, et al. Graphene Oxides show angiogenic properties. Adv Healthc Mater. 2015;4(11):1722–1732. DOI:https://doi.org/10.1002/adhm.201500155.
   PubMed Web of Science ®Google Scholar
• Chen M, Wu D, Tu S, et al CRISPR/Cas9 cleavage triggered ESDR for circulating tumor DNA detection based on a 3D graphene/AuPtPd nanoflower biosensor. Biosens Bioelectron. 2020;173:112821.
   PubMed Web of Science ®Google Scholar
• Yue H, Zhou X, Cheng M, et al. Graphene oxide-mediated Cas9/sgRNA delivery for efficient genome editing. Nanoscale. 2018;10(3):1063–1071. DOI:https://doi.org/10.1039/C7NR07999K.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen L, Chen J, et al. Stability, cellular uptake, and in vivo tracking of zwitterion modified graphene oxide as a drug carrier. Langmuir. 2019;35(5):1495–1502. DOI:https://doi.org/10.1021/acs.langmuir.8b01995.
   PubMed Web of Science ®Google Scholar
• Mahdavi M, Fattahi A, Nouranian S. doxorubicin stability and retention on pegylated graphene oxide nanocarriers adjacent to human serum albumin. ACS Appl Bio Mater. 2020;3(11):7646–7653.
   PubMedGoogle Scholar